New RH5-based malaria prophylaxis with stronger infection inhibition

Figure (above) taken from Alanine et al., 2019

Applications: Malaria vaccine design, biologics, antimalarial drug development

RH5 is the leading target for blood-stage malaria vaccines. Now, human mAbs have been isolated and studied for the first time, providing strategies for biologics development, vaccine design and seasonal prophylactic use.

Features	Benefits
Identification of neutralising (blue) and non-neutralising (green) mAbs that together bind RH5 to synergistically inhibit merozoite (MZ) invasion of red blood cells (RBC)	Facilitate structure-guided prophylaxis and biologics development to maximize antibody efficacy against blood-stage malaria
Potentiation of neutralising antibodies by non-neutralising antibodies	Antimalarial antibody combinations that neutralise merozoites with a higher potency than ever before
Uses human antibodies	Better for human drug development than animal-derived antibodies
Multiple, distinct neutralising binding sites identified	Increased targeting to enhance neutralisation

Patented & Available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

New RH5-based malaria prophylaxis with stronger infection inhibition

Ready to get in touch?